Listen to our latest Investing Matters Podcast episode 'Uncovering opportunities with investment trusts' with The AIC's Richard Stone here.
https://www.cityam.com/healthy-dose-british-ingenuity-money-patents-and-patience/amp/
Notice the “stockpile”
7 weeks of trials is it ? Furthermore no negative points following either dose or it would have been stopped.
The first patient dosed in the UK is at home happily with her family ( must be good ) phwoar !!! We are flying !
Have the after hours buys stopped ? If so, do we know of a value that was collated ?
Is there a specific time in the day a TR-1 needs to drop ? If not CT did mention yesterday that he had a day and a half for his news to drop and was fairly confident. Let’s give him a chance for the rest of the day.
https://medicalxpress.com/news/2021-03-oral-covid-treatment-yields-trial.amp
Synairgen - An Investment Brief by Rupert Marlow – 3rd March 2021
*Please read the disclaimer at the end of this note*
LON: SNG
OTC: SYGGF
FRA: OMY
* **Synairgen’s inhaled antiviral, SNG001, reduced progression to severe disease by 79% in a UK Phase II Trial for hospitalised Covid-19 patients**
* **Results due shortly for further Phase II and III Covid-19 Trials in UK, US and globally**
* **Assuming these confirm earlier results, approvals and significant orders should follow**
* **Potential for stockpiling against future pandemics and in COPD market**
# Summary
Synairgen is a UK-based biotech that has developed an inhaled treatment, called SNG001, which evidence suggests is a highly promising drug in the fight against Covid-19. Originally, and still, intended as a broad-spectrum, respiratory antiviral, it has a naturally-occurring protein, interferon beta-1a, as its active ingredient. SNG001 is currently in several Covid-19 trials awaiting results, and for a company of its size to have made the progress it has is an astonishing achievement.
The trials in progress are as below. SG018 includes a Long Covid-19 study that will report possibly in Q3 2021:
![img](as1onc98nuk61)
The [ACTIV-2 trial](https://www.nih.gov/news-events/news-releases/four-potential-covid-19-therapeutics-enter-phase-2-3-testing-nih-activ-2-trial) is under Operation Warp Speed, and will be especially important in determining Synairgen’s future. At any time, we may get an indication of a switch from Phase II to Phase III, which would be a strongly positive signal.
SNG001 has three strong competitive advantages. First, evidence suggests that it is particularly effective, possibly unrivalled, in the early stages of disease progression. Secondly, its being agnostic, as opposed to virus-specific, means it will work against mutant variants of Covid-19. Thirdly, it is easy to administer.
But SNG001 is potentially much more than a Covid-19 therapeutic. Governments will need to stockpile effective agnostic antivirals against future respiratory epidemics, and SNG001 has shown promise as an antiviral for COPD patients. Placing a value on all this is difficult, and although this note suggests a target price of £8, SNG001 is likely to be either a comparative failure or an emphatic success. There are sound reasons for thinking the latter is more probable, but the risks are unusually high.
# Background
Synairgen was established in 2003 by three professors from Southampton University, and its shares were listed on AIM in June 2005. The first project was to assemble a BioBank of samples in order to build models of respiratory diseases, particularly asthma and COPD (chronic obstructive pulmonary disease), and research how these might be treated.
In time this led to the development of SNG001, which is inhaled directly into the lungs, in a formulation that is pH neutral, once a day for 14 days, by means of an Aerogen S